Abstract: Devices, systems, and methods for medication infusion are described herein. In some embodiments, a system includes a patient access subassembly, a first fluid reservoir, a second fluid reservoir, and an assembly. The assembly can have a first configuration in which the patient access subassembly is in fluid communication with the first fluid reservoir via a first tube, a second configuration in which the first fluid reservoir is in fluid communication with the second fluid reservoir, and a third configuration in which the first fluid reservoir is in fluid communication with the patient access subassembly via a second tube, the first fluid reservoir fluidically isolated from the first tube in the third configuration.

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGF? trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

Abstract: Provided herein are methods of treating and preventing a disorder selected from the group consisting of an autoimmune disorder, inflammatory disorder, immune disorder, bone and joint disorder, neurodegenerative disorder, and neuromuscular disorder in a. subject in need thereof. The method includes administering an effective amount of an organonitro or sulfoxyalkyl organonitro compound to the subject, which may include using a dosing regimen that comprises administering loading and maintenance doses.

Abstract: The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.

Abstract: Devices, systems, and methods for medication infusion are described herein. In some embodiments, a system includes a patient access subassembly, a first fluid reservoir, a second fluid reservoir, and an assembly. The assembly can have a first configuration in which the patient access subassembly is in fluid communication with the first fluid reservoir via a first tube, a second configuration in which the first fluid reservoir is in fluid communication with the second fluid reservoir, and a third configuration in which the first fluid reservoir is in fluid communication with the patient access subassembly via a second tube, the first fluid reservoir fluidically isolated from the first tube in the third configuration.

Abstract: The present invention relates to a composition comprising solid crystalline, non-impact or non-detonation sensitive particles comprising 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), methods of preparing the crystalline form, and its use.

Abstract: The present disclosure relates to compositions and methods for producing a recombinant virus, e.g., a recombinant oncolytic adenovirus, using an A549 host cell.

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGF? trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

Abstract: Devices, systems, and methods for medication infusion are described herein. In some embodiments, a system includes a patient access subassembly, a first fluid reservoir, a second fluid reservoir, and an assembly. The assembly can have a first configuration in which the patient access subassembly is in fluid communication with the first fluid reservoir via a first tube, a second configuration in which the first fluid reservoir is in fluid communication with the second fluid reservoir, and a third configuration in which the first fluid reservoir is in fluid communication with the patient access subassembly via a second tube, the first fluid reservoir fluidically isolated from the first tube in the third configuration.

Abstract: The invention relates to a recombinant adenovirus comprising two or more therapeutic transgenes, e.g., two components of a heterodimeric cytokine, separated by a cleavable linker.

Abstract: The invention relates to a method for producing a recombinant virus, e.g., a recombinant oncolytic adenovirus, using an A549 host cell.

Abstract: Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-OOI and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-OOI to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing ?-rays, ?-rays, ?-rays, neutron radiation, or a combination thereof.

Abstract: The invention provides compositions and methods for administering a therapeutic agent to a patient, such as pharmaceutical compositions containing a blood product and a therapeutic agent selected from an anthracycline anti-cancer agent (e.g., doxorubicin), a topoisomerase inhibitor, an oxazaphosphinanyl anti-cancer agent, a nitro-aryl anti-cancer agent, a thiol-reactive functional-group agent, a nitric oxide modulator, a platinum-based antineoplastic compound, acrylamide, acrylonitrile, bis(4-fluorobenzyl)trisulfide, a cardiac glycoside, an anti-mitotic agent (e.g., paclitaxel), a nucleoside analog, an EGFR inhibitor, or an anti-microbial agent.

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

Abstract: The invention provides compositions and methods for administering a therapeutic agent to a patient, such as pharmaceutical compositions containing a blood product and a therapeutic agent selected from an anthracycline anti-cancer agent (e.g., doxorubicin), a topoisomerase inhibitor, an oxazaphosphinanyl anti-cancer agent, a nitro-aryl anti-cancer agent, a thiol-reactive functional group agent, a nitric oxide modulator, a platinum-based antineoplastic compound, acrylamide, acrylonitrile, bis(4-fluorobenzyl)trisulfide, a cardiac glycoside, an anti-mitotic agent (e.g., paclitaxel), a nucleoside analog, an EGFR inhibitor, or an anti-microbial agent.

Abstract: The present disclosure relates to recombinant human adenoviruses engineered to express a structural protein of a coronavirus. The recombinant adenoviruses are suitable for active immunization against a coronavirus in a human subject. Additionally, immune globulin obtained from immunized human subjects is suitable for passive immunization of a coronavirus-infected human subject.

Abstract: The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), including formulations containing, autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous infusion without any significant pain at the site of infusion.

Abstract: The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.

Abstract: The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.

Abstract: The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), including formulations containing autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous infusion without any significant pain at the site of infusion.